Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000824 · ClinicalTrials.gov registry record · NA
A Study of Cytotoxic T Lymphocyte (CTL) Therapy in HIV-Infected Patients
A NA study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Terminated
- Registry status
- NA
- Development phase
NCT00000824: Clinical Trial NA study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT00000824 is a NA study that was terminated before completion, run by National Institute of Allergy and Infectious Diseases (NIAID). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00000824, a NA study, was terminated before completion, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- TERMINATED
- Registry status
- NA
- Development phase
Study Summary
To define the safety of cytotoxic T lymphocytes (CTLs) generated from sibling-supplied dendritic cells and lymphocytes and infused into an HIV-infected patient. To determine the efficacy of these CTLs in helping the immune system to fight HIV. With lower CD4 counts, HIV-infected patients may not be able to produce dendritic cells and lymphocytes, special types of immune cells that generate HIV-specific CTLs. Infusion of CTLs generated from the dendritic cells and lymphocytes of an HIV-negative sibling may enable the body to recognize HIV more readily and increase immune response against the virus.
Interventions
- DRUG Lymphocytes, Activated
Trial Details
| Field | Value |
|---|---|
| Est. Completion | 2005-06 |
| Phase | NA |
Why NCT00000824 stopped before completion
NCT00000824 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which Lymphocytes, Activated is the first listed.
NCT00000824 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00000824 about?
NCT00000824 is a clinical study titled "A Study of Cytotoxic T Lymphocyte (CTL) Therapy in HIV-Infected Patients". To define the safety of cytotoxic T lymphocytes (CTLs) generated from sibling-supplied dendritic cells and lymphocytes and infused into an HIV-infected patient. To determine the efficacy of these CTLs in helping the immune system to fight HIV. With lower CD4 counts, HIV-infected patients may not be...
What is the current status of trial NCT00000824?
This trial is currently terminated. It is a NA study. Estimated completion is 2005-06.
What interventions are being tested in trial NCT00000824?
The interventions under investigation include: Lymphocytes, Activated (DRUG).
Who is sponsoring clinical trial NCT00000824?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.